Combined therapy of imatinib and an anti-CTLA4 immune-checkpoint inhibitor

被引：7
|
作者：
Park, Kinam [1 ]
机构：
[1] Purdue Univ, Biomed Engn & Pharmaceut, W Lafayette, IN 47907 USA
来源：
JOURNAL OF CONTROLLED RELEASE | 2018年 / 281卷
关键词：
D O I：
10.1016/j.jconrel.2018.06.011
中图分类号：
O6 [化学];
学科分类号：
0703 ;
摘要：
引用
收藏
页码：196 / 196
页数：1
相关论文
共 50 条
  • [1] The Prembion® pre-biotic improves the impact of anti-CTLA4 immune checkpoint inhibitor in a murine model of malignant pleural mesothelioma
    Gattlen, C.
    Chriqui, L-E
    Hao, Y.
    Gonzalez, M.
    Krueger, T.
    Siankevich, S.
    Dyson, P.
    Cavin, S.
    Perentes, J-Y
    BRITISH JOURNAL OF SURGERY, 2022, 109 (SUPPL 3)
  • [2] Advances of immune-checkpoint inhibition of CTLA-4 in pancreatic cancer
    Ni, Ran
    Hu, Zhiming
    Tao, Ran
    BIOMEDICINE & PHARMACOTHERAPY, 2024, 179
  • [3] An adapted anti-CTLA4 therapeutic aimed at mitigating the toxicities of checkpoint inhibition
    Naidoo, Jarushka
    Dykema, Arbor
    D'Alessio, Franco
    JOURNAL OF CLINICAL INVESTIGATION, 2019, 129 (01): : 75 - 77
  • [4] Pickering emulsions with ethiodized oil and nanoparticles for slow release of intratumoral anti-CTLA4 immune checkpoint antibodies
    Tselikas, Lambros
    de Baere, Thierry
    Isoardo, Thomas
    Susini, Sandrine
    Ser-Le Roux, Karine
    Polrot, Melanie
    Adam, Julien
    Rouanne, Mathieu
    Zitvogel, Laurence
    Moine, Laurence
    Deschamps, Frederic
    Marabelle, Aurelien
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (01)
  • [5] Opportunistic autoimmune disorcers potentiated by immune-checkpoint inhibitors anti-CTLA-4 and anti-PD-1
    Kong, Yi-chi M.
    Flynn, Jeffrey C.
    FRONTIERS IN IMMUNOLOGY, 2014, 5
  • [6] Thyroid Immune-Related Adverse Events in Patients with Cancer Treated with anti-PD1/anti-CTLA4 Immune Checkpoint Inhibitor Combination: Clinical Course and Outcomes
    Lui, David Tak Wai
    Lee, Chi Ho
    Tang, Vikki
    Fong, Carol Ho Yi
    Lee, Alan Chun Hong
    Chiu, Joanne Wing Yan
    Leung, Roland Ching Yu
    Kwok, Gerry Gin Wai
    Li, Bryan Cho Wing
    Cheung, Tan To
    Woo, Yu Cho
    Lam, Karen Siu Ling
    Yau, Thomas
    ENDOCRINE PRACTICE, 2021, 27 (09) : 886 - 893
  • [7] CTLA-4, an Essential Immune-Checkpoint for T-Cell Activation
    Chikuma, Shunsuke
    EMERGING CONCEPTS TARGETING IMMUNE CHECKPOINTS IN CANCER AND AUTOIMMUNITY, 2017, 410 : 99 - 126
  • [8] Immune checkpoint inhibitor (anti-CTLA-4, anti-PD-1) therapy alone versus immune checkpoint inhibitor (anti-CTLA-4, anti-PD-1) therapy in combination with anti-RANKL denosumuab in malignant melanoma: a retrospective analysis at a tertiary care center
    Afzal, Muhammad Z.
    Shirai, Keisuke
    MELANOMA RESEARCH, 2018, 28 (04) : 341 - 347
  • [9] Morphology of immune-mediated hepatitis: A comparison between immune checkpoint inhibitor therapy and combined immune checkpoint inhibitor/anti-angiogenic therapy
    Zhang, Qiongyan
    Chen, Lingli
    Guo, Xinxin
    Shen, Licheng
    Huang, Yufeng
    Chen, Yi
    Zhang, Ningping
    Ge, Ningling
    Gao, Hong
    Zhang, Wen
    Hou, Yingyong
    Ji, Yuan
    ANNALS OF DIAGNOSTIC PATHOLOGY, 2024, 68
  • [10] Immune-checkpoint Inhibitor in clinical practice
    Fujiwara, Yutaka
    ANNALS OF ONCOLOGY, 2015, 26 : 69 - 69
12345